A multicenter, randomized, placebo‐controlled, double‐blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15‐0444 in patients with type 2 diabetes - Concepedia

Concepedia

Publication | Closed Access

A multicenter, randomized, placebo‐controlled, double‐blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15‐0444 in patients with type 2 diabetes

39

Citations

20

References

2010

Year

Eun‐Jung Rhee, Won‐Young Lee, Kun‐Ho Yoon, Soon Jib Yoo, I. K. Lee, Sei Hyun Baik, Y. K. Kim, M.‐K. Lee, Kyong Soo Park, J. Y. Park,

Diabetes Obesity and Metabolism

Abstract

LC15-0444 monotherapy (50 mg for 12 weeks) improved the HbA1c, FPG level, oral glucose tolerance test results, β-cell function and insulin sensitivity measures, and was well tolerated in Korean subjects with type 2 diabetes.

References

	Year	Citations

Page 1